THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 121 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $484 | -5.5% | 57 | 0.0% | 0.00% | – |
| Q1 2024 | $512 | -20.1% | 57 | 0.0% | 0.00% | – |
| Q4 2023 | $641 | +30.3% | 57 | 0.0% | 0.00% | – |
| Q3 2023 | $492 | -16.6% | 57 | 0.0% | 0.00% | – |
| Q2 2023 | $590 | -4.7% | 57 | 0.0% | 0.00% | – |
| Q1 2023 | $619 | -38.1% | 57 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | – | 57 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 57 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 57 | 0.0% | 0.00% | -100.0% |
| Q1 2020 | $1,000 | – | 57 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
| Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
| Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
| Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
| Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
| Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
| Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
| Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |